Growing fear of MERS virus increases urgency of researchers

MERS has killed 181 people worldwide, but its appearance in the U.S. this month surprised authorities. Researchers at NovaVax are using a new method to develop vaccines, which could decrease the decade-long timeline and $1 billion cost associated with vaccine development.

By Nicole Gray • May 22, 2014

FDA grants orphan drug status to AbbVie's Humira

AbbVie's Humira has been granted orphan drug status for the treatment of uveitis. It is currently a $2.6 billion drug used to treat various inflammatory conditions.

By Nicole Gray • May 21, 2014

Explore the Trendline➔

Vaccine development

Vaccine developers are investing in shots for RSV, influenza and pneumococcal disease in a newly uncertain regulatory climate.

By BioPharma Dive staff

Bristol-Myers Squibb gains 'breakthough therapy' designation for cancer drug

The pharmaceutical company gains the designation from the FDA for an oncology product being developed for the treatment of multiple myeloma.

By Nicole Gray • May 21, 2014

FDA: Fluzone not linked with febrile seizures

After a CDC warning that Fluzone may be linked to the increase in febrile seizures during the winter of 2010-11, researchers looked at epidemiologic data. Their analysis confirmed no significant association.

By Nicole Gray • May 16, 2014

Cetirix Orthopaedics obtains new financing, patents

Ceterix Orthopaedics, which makes surgical equipment for arthroscopic procedures, received two new patents and a new round of financing. 

By Nicole Gray • May 16, 2014